Axtria Thought Leadership

Executive insights and perspectives on the Life Sciences industry


Biosimilars In The US - Will They Deliver On The Promise?

Blog

Biosimilars In The US – Will They Deliver On The Promise?

Research presented from Mylan Pharmaceuticals at the recently held 2016 annual meeting of the American Society of Clinical Oncology (ASCO) generated excitement within the medical c ...

White Paper

Driver Score – The New Paradigm

Of late, telematics as a disruptive technology is rapidly gaining attention in shaping the future. New industries are accepting this revolution and are moving to data-backed decisi ...

Commercial Operations Capabilities Excellence And Business Performance

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

White Paper

At Supplier Management Crossroads? – Choose The Right Approach

Of late, regulators have started focusing attention on the way banks and financial institutions are managing the risk in their supplier management programs. ...

Challenges To Traditional Pharma Incentive Compensation Plan Design

White Paper

Challenges To Traditional Pharma Incentive Compensation Plan Design

Changes in emerging environmental trends facing the pharma industry are requiring companies to rethink different strategic and operational sales force plans that ultimately drive n ...

White Paper

Deploying K-Nearest Neighbor Modeling Methodologies For Real World Problems

There has been an immense improvement of theory and algorithms in recent times leading to enhancement in computation power. Also, online data availability was never easier than now ...

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

White Paper

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to ...

White Paper

A Mathematical Framework For Privacy Risk

In recent trends, people’s attitude towards the internet has changed tremendously. The willingness and comfort level of people to share and reveal information about themselves an ...

White Paper

Basel Downturn – Identification & Estimation

As part of Basel accords, banks and other financial institution should hold sufficient capital to buffer against large unexpected losses. Minimum capital required, for pillar 1, is ...

Start typing and press Enter to search